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Introduction. Our study aims to determine the prevalence of nicotine dependence and investigate the effect of nicotine dependence
on psychopathology among schizophrenia patients.Methods. A cross-sectional study was carried out in an outpatient psychiatric
clinic at a general hospital in Malaysia. 180 recruited subjects were administered the Malay version of Mini International
Neuropsychiatric Interview (MINI), the Positive and Negative Symptom Scale (PANSS), and the Malay version of Fagerstrom
Test for Nicotine Dependence (FTND-M) questionnaires. Results. The prevalence of nicotine dependence among the subjects
was 38.1% (𝑛 = 69) and they were mainly composed of male gender, Malay ethnicity, being treated with atypical antipsychotics,
and taking other illicit drugs or alcohol. Subjects with severe nicotine dependence scored less in the negative subscale of PANSS
compared with the nonsmokers (𝑃 = 0.011). On performing the hierarchymultiple regressions, dependence status still significantly
predicted negative scores after adjusting the confounders (𝑡 = −2.87, 𝑃 = 0.005). Conclusion. The rate of nicotine use disorder
among schizophrenia patients in this study is higher than that of the general population in Malaysia. The significant association
between nicotine dependence and negative psychopathology symptoms will help the healthcare practitioners in their management
of nicotine dependence among schizophrenia patients.
1. Introduction
Schizophrenia is a severe and disabling mental illness [1].
Persons with schizophrenia are at high risk of shorter life
expectancy [2–4], due to the increased mortality related to
circulatory and respiratory diseases, with chronic cigarette
smoking being a major contributory factor [5, 6].
Worldwide statistics have shown that smoking con-
tributes significantly to mortality [7, 8], with nicotine being
more addictive than alcohol, marijuana, or cocaine [9].
Compared to the general healthy population, the prevalence
of smoking is found to be much higher among people
with psychotic disorders [10–12] and, among those suffering
from schizophrenia, the occurrence of smoking and nicotine
dependence is higher than that of both the general population
and those with other mental illnesses [13–17]. Schizophrenic
patients who smoke tend to have higher frequency of heavy
smoking [8, 12], with rates ranging from 60% [16] to as high
as 80% [18]. In addition, they are less likely to quit smoking
[12, 19–22]. Hence, it is not surprising that smokers with
psychiatric disorders suffer higher rates of morbidity and
mortality secondary to smoking related illnesses [22, 23].
Smoking is the leading preventable cause of morbidity
and premature mortality [24–26]. In Malaysia, one out of
every five deaths is related to smoking. This is significant as
smoking is themost importantmodifiable cause of premature
death, responsible annually for an estimated 120,000 years of
potential life loss [27]. The objective of this study is therefore
to assess the prevalence of smoking and nicotine dependence
among schizophrenic patients in a general hospital and to
determine its associated factors, including the severity of
illness.
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2. Methods
180 patients were recruited from the outpatient psychiatric
clinic in a general hospital from August to November, 2011,
via purposive samplingmethod.The clinic had two follow-up
sessions eachweek, with an average of 100–160 patients, and it
covered awide spectrumof psychiatric cases. It was estimated
that 50–60%of the attendeesmet the diagnosis of schizophre-
nia. Inclusion criteria were patients who (a) met DSM-IV-
TR [28] criteria for schizophrenia, (b) were at least 18 years
of age, (c) provided informed consent, and (d) were able to
understand and communicate in English or Bahasa Malaysia
in order to complete the study measurements. Exclusion
criteria were those who (a) had Axis I diagnosis other than
schizophrenia or substance use disorder, (b) had an organic
mental disorder, (c) had a diagnosis of mental retardation,
(d) were experiencing unstable general medical conditions,
and (e) were grossly psychotic and unable to cooperate
with the interviewer. All patients who were identified as
having schizophrenia in the clinic were approached. Written
informed consent was obtained from patients who chose to
participate in the study, after the discussion of study details
with the researcher. 19 patients were excluded due to various
reasons. The study was conducted in accordance with the
Declaration of Helsinki and the National Medical Research
Registry of the Ministry of Health and The Ministry of
HealthMedical ResearchEthical Committee, which approved
and monitored the study (Ethical committee reference no.
NMRR-11-697-9166).
The study was conducted by a single interviewer who was
trained in the use of the study instruments. A demographic
and clinical data sheet was used to aid in the collection of
the variables addressed in the study which, among others,
included gender, ethnicity, medication use (typical or atypical
antipsychotic), and history of substance use (lifetime use
of alcohol, opioid, metamphetamine, cannabis, and ecstasy).
This information was gathered via direct interview and/or
review of patient’s clinical records. The subjects were admin-
istered theMalay version ofMini International Neuropsychi-
atric Interview (MINI), the Positive and Negative Symptom
Scale (PANSS) to rate the symptoms of schizophrenia [29],
and the Malay version of Fagerstrom Test for Nicotine
Dependence (FTND-M) [30]. The interview was completed
with the subjects performing a breath test to measure the
levels of carbon monoxide in their exhaled air, by using
the simple handheld breath analyzer (piCO+ Smokerlyzer).
This instrument provided a direct measure of the carbon
monoxide in parts per million (CO ppm). The MINI is a
short structured diagnostic interview for researchers to accu-
rately determine the presence of any psychiatric disorders
according to DSM-IV or ICD-10 [31, 32]. It was administered
in either English or in the Malay language, according to
the patient’s preference and main spoken language. Previous
research has shown that 39.4% of smokers failed to meet the
DSM-IV-TR criteria for nicotine dependence [33]. Hence,
the FTND-M was used to assess the nicotine dependence
among schizophrenia patients in this study. This easy-to-use
self-report questionnaire is noninvasive, low-cost, and easy
to score and has good validity and reliability for determining
nicotine dependence among the smokers [30]. In our study,
the patients were categorized as nicotine dependent if they
had a score of more than two of that on the FTND-M
[30]. Furthermore, all the nicotine-dependent patients were
further classified as having high/severe dependence (FTND-
M > 6) or mild-moderate dependence (FTND-M ≤ 6), as
defined in previous studies [34, 35].
2.1. Statistical Analysis. Analyses of data were performed
using the Statistical Package for Social Studies (SPSS) to
generate the relevant descriptive epidemiological statistics.
Differences between nicotine dependence and nonnicotine
dependence on categorical variables were tested using either
the chi-squared test or Fisher’s exact test. To examine the rela-
tionship between nicotine dependence and psychopathol-
ogy (PANSS), multivariate general linear model approach
was used, with covaried gender, ethnicity, use of atypical
antipsychotic medication, and comorbid use of illicit drug
or alcohol, with familywise error multiple testing corrections
where appropriate. A bootstrap analysis was conducted, using
Preacher and Hayes’ indirect macro for SPSS, to examine the
indirect effect of nicotine dependence (independent variable)
and psychopathology (dependent variable). For each analysis,
1000 random samples of the original size were taken from
the obtained data, replacing each value as it was sampled.
Statistical significance was evaluated at the <0.05 level using
two-sided test.
3. Results
The study group comprised predominantly males (64.1%,
𝑛 = 116) with the mean age of 41.5 years old (SD = 11.41).
The current prevalence of nicotine dependence in the study
subjects was found to be 38.1% (𝑛 = 69). The exhaled carbon
monoxide in parts per million was correlated positively with
FTND-M scores (Pearson’s rho = 0.739, 𝑃 < 0.01). The
mean number of cigarettes smoked in the sample was 17
sticks per day. Among the subjects who were smoking, they
have been smoking for a mean of 19.94 years and they have
started smoking at the mean age of 19.7 years (SD 6.25).
In 37% of the subjects, there was a positive family history
of smoking. Sociodemographic characteristics and clinical
details, according to smoking status, are shown in Table 1.
Multivariate analysis of covariance was used to exam-
ine the relationship between nonsmokers (𝑛 = 112,
61.9%), smokers with severe nicotine dependence (𝑛 =
21, 11.6%), mild-moderate nicotine dependence (𝑛 = 48,
26.5%), and PANSS scores, while controlling the gender,
ethnicity, use of atypical antipsychotic medication, income,
and comorbid using illicit drug or alcohol (Table 2). The
nicotine dependence status was significantly associated with
the PANSS scores (Wilk’s lambda 0.898; 𝐹(2.37) = 2.78;
𝑃 = 0.017). We conducted pairwise comparisons of the
total and subscale PANSS scores between nonsmokers, those
with mild dependence and those with severe dependence,
using Bonferroni familywise error multiple testing correc-
tions. Those with severe nicotine dependence scored less in
the negative subscale compared to that of the nonsmokers
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Table 1: Sociodemographic characteristics and clinical features according to nicotine dependence.
Characteristics
Nicotine
dependence
Nonnicotine
dependence Statistic 𝑃 OR/mean difference(95% CI)
𝑛 = 69 𝑛 = 112
Age, years: mean (s.d.) 39.6 (10.8) 42.6 (11.6) 0.087
Male, 𝑛 (%) 68 (98.6) 48 (42.9) 𝜒2 = 57.5 ∗∗<0.001 90.6 (12.1–676)
Ethnicity, 𝑛 (%)
Malay 41 (49.4) 42 (37.5)
Chinese 20 (29) 50 (44.6) 𝜒2 = 8.3 ∗∗<0.001
Indian 8 (11.6) 20 (17.90)
Duration of illness, years: mean
(s.d.) 13.9 (10.4) 15.6 (9.8) 0.287
Atypical antipsychotic, 𝑛 (%) 46 (66.7) 53 (53.5) 𝜒2 = 6.4 ∗∗0.014 2.23 (1.19–4.15)
Chlorpromazine equivalents
(mg), mean (s.d.) 276.8 (190.6) 291.1 (487.0) 0.816
Taking illicit drugs/alcohol, 𝑛 (%) 19 (27.5) 2 (1.8) 𝜒2 = 27.6 ∗∗<0.01 0.05 (0.01–0.21)
Fagerstrom Test for Nicotine
Dependencescore, mean (s.d.) 4.16 (2.36) —
CO ppm (s.d) 13.91 (7.16) 2.22 (0.65) ∗∗<0.01 11.69 (9.97–13.42)
Marital status, 𝑛 (%)
Single 50 (72.5) 72 (64.3) 0.22
Divorced 2 (2.9) 1 (0.9)
Married 17 (24.6) 39 (34.8)
Employment, 𝑛 (%)
Employed 41 (59.4) 55 (49.1) 0.22
Unemployed 28 (40.6) 57 (50.9)
Total income, 𝑛 (%)
≤RM500 43 (62.3) 92 (82.1) ∗0.014 11.35 (0.011–0.017)
RM501–1000 15 (21.7) 15 (13.4)
RM1001–2000 6 (8.7) 2 (1.8)
RM2001–3000 4 (4.8) 3 (2.7)
>RM3000 1 (1.4) 0
Education level, 𝑛 (%)
Primary 10 (14.5) 15 (13.4)
Secondary 53 (76.8) 75 (67) 0.22
College/university 6 (8.7) 21 (18.8)
No education 0 1 (0.9)
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01, s.d. = standard deviation, OR = odds ratio, CI = confidence interval, and CO ppm = carbon monoxide in parts per million.
(𝑃 = 0.015). On performing the hierarchy multiple regres-
sions, dependence status still significantly predicted negative
scores after adjusting the confounders (𝑡 = −2.87,𝑃 = 0.005).
4. Discussion
Based on all the literature reviewed, prevalence of smoking
is found to be high among people with schizophrenia and
our current study found a similar pattern. The prevalence of
nicotine dependence found in this study was 38.1% (𝑛 = 69)
with the subjects being more likely to be male and from the
Malay ethnic group. They were also more likely to be taking
illicit drugs or alcohol and were on atypical antipsychotic
treatment. The findings of this study showed that subjects
with severe nicotine dependence had less severity in negative
symptoms compared to the nonnicotine dependent subjects.
The smoking rate of this study was much lower than it
was reported in some studies done in the west [8, 16, 36] and
among schizophrenic patients in a Chinese population [37].
The possible reason for the lower prevalence of nicotine use
disorder in this study could be related to the lower prevalence
of nicotine use among the Malaysian general population,
estimated to be 23.1%, compared to other countries, which
ranged from 27% to 43.3% [38].
There has been no study on ethnicity, though theNational
Health and Morbidity Survey 1996 found that Malay men
were more likely to smoke [39]. Other studies have shown
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Table 2: Hierarchical multiple regression between smoking severity and PANSS scores.
Nonsmoker
Mild-moderate
nicotine
dependence
Severe
nicotine
dependence
N −M
Mean difference
N − S
Mean difference
M − S
Mean difference
𝑛 = 112 𝑛 = 48 𝑛 = 21
Total PANSS score, mean, amean
(s.d)
49.13 51.56 51.43 0.62 1.16 0.54
50.33a (10.28) 49.71a (12.21) 49.17a (9.22) (𝑃 = 0.98) (𝑃 = 0.95) (𝑃 = 0.97)
Positive subscale score, mean,
amean (s.d)
8.54 9.65 9.76 −0.09 −0.04 0.05
8.94a (2.64) 9.04a (3.09) 8.99a (3.93) (𝑃 = 0.88) (𝑃 = 0.95) (𝑃 = 0.98)
Negative subscale score, mean,
amean (s.d)
18.01 17.13 14.67 1.89 4.54 2.64
18.41a (5.67) 16.52a (6.45) 13.87a (4.48) (𝑃 = 0.26) (∗𝑃 = 0.011) (𝑃 = 0.06)
General psychopathology
subscale score, mean, amean (s.d)
22.70 24.02 24.14 0.50 0.65 0.14
23.42a (4.13) 22.92a (6.27) 22.77a (7.07) (𝑃 = 1) (𝑃 = 1) (𝑃 = 1)
N, nonsmoker; M, mild-moderate nicotine dependence; S, severe nicotine dependence; and PANSS = Positive and Negative Syndrome Scale.
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01, s.d = standard deviation.
aMultivariate analysis of covariance with PANSS total score and subscale scores as dependent variables; covariates appearing in the model are evaluated at the
following values: gender = 1.36, ethnicity = 1.70, drug and alcohol abuse = 1.12, income = 1.25, and atypical antipsychotic = 1.55. These tests are based on the
linearly independent pairwise comparisons among the estimated marginal means and adjusted for multiple comparisons using Bonferroni familywise error
correction.
similar male preponderance [10, 37], concurrent hazardous
use of alcohol and other illicit drugs [8, 11, 15], with studies
suggesting that smoking is a reliable clue for other substance
use and abuse [8] including alcohol [40, 41].
Smoking alters the level and effectiveness of medications
in the blood, as it is hypothesized that nicotine interacts
with many of the same central pathways thought to be
abnormal in persons with schizophrenia [8, 36, 42]. Smoking
also increases the metabolism of neuroleptics [43–45], with
studies showing that individuals with schizophrenia and
smoking tend to receive consistently higher doses of antipsy-
chotics compared to nonsmokers [14, 46, 47]. The choice
of pharmacological treatment is likely to have influence on
smoking behavior [48], as earlier studies found that typical
antipsychotics were associated with increased smoking in
some individuals [49, 50] and they had greater difficulty
to quit smoking [36]. Several reports have suggested that
atypical antipsychotics, namely, clozapine, have helped in the
reduction of smoking among schizophrenic smokers who
have switched to this medication [51, 52]. In a small group of
patients with schizophrenia or schizoaffective disorder, who
were treated with transdermal nicotine patches and atypical
or typical antipsychotic medications, George et al. [36] found
a more favorable cessation rates among smokers who had
received risperidone and olanzapine, compared to those on
typical antipsychotics.
The literature is divided into smoking and symptoms
of schizophrenia [10, 53]. In this present study, subjects
who were severely nicotine dependent scored less in the
PANSS negative symptoms. This finding seemed to be in
agreement with other previous studies which showed that
smokers had lower negative symptoms [6, 54–56]. A pre-
clinical trial came up with evidence that nicotine affected
several neurotransmitter systems, including dopamine, glu-
tamate, and 𝛾-aminobutyric acid (GABA), and certain neu-
rocognitive deficits associated with these neurotransmitters
improved after nicotine was administered in patients with
schizophrenia. However, dopamine has been found to be
the most implicated when the relationship between nicotine
use and negative symptoms was studied [57]. By stimulating
the release of dopamine in the nucleus accumbens and
prefrontal cortex, nicotine reduces the negative symptoms of
schizophrenia, explaining its use as a form of self-medication
[58].These positive effects could be an important mechanism
that explains the comorbidity of schizophrenia and nicotine
dependence [59].
Our study has several limitations that need to be high-
lighted. Firstly, as the information collection was done via
self-reporting, it raised the possibility of underestimating the
other substances. Secondly, it was not possible to identify
a causal relation between the association of smoking and
nicotine dependence and other variables because of the
cross-sectional design of this study. Thirdly, there was no
comparison made with a control group. Nevertheless, our
study was able to prove that smoking is not only prevalent
among the study subjects but reflects the severity of patients’
illness.
5. Conclusion
The rate of nicotine use disorder among schizophrenia
patients in this study is higher than that of the general popu-
lation in Malaysia. Although causal links cannot be inferred,
our study found a significant association between nicotine
dependence and negative psychopathology symptoms, which
will be an added value for the healthcare practitioners in their
management of nicotine dependence among schizophrenic
patients.
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